PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-12.38%
Both yoy net incomes decline, with AXSM at -36.62%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-27.15%
Negative yoy D&A while AXSM is 2.71%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-5631.45%
Negative yoy deferred tax while AXSM stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
0.93%
Less SBC growth vs. AXSM's 17.08%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
-32.67%
Negative yoy working capital usage while AXSM is 54.83%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
107.56%
Lower AP growth vs. AXSM's 491.12%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
-665.24%
Both reduce yoy usage, with AXSM at -42.83%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
5631.45%
Well above AXSM's 3407.39%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-36.10%
Both yoy CFO lines are negative, with AXSM at -21.11%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
78.08%
Some CapEx rise while AXSM is negative at -173.79%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
78.08%
We have mild expansions while AXSM is negative at -173.79%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
66.67%
Debt repayment growth of 66.67% while AXSM is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
210.14%
Lower share issuance yoy vs. AXSM's 131400497.78%, implying less dilution. David Dodd would confirm the firm still has enough capital for expansions.
No Data
No Data available this quarter, please select a different quarter.